Estuary Biotherapeutics Launches With $103 Million To Develop Gene Therapies For Kidney Disease
By Amit Chowdhry ● Today at 8:37 AM
Estuary Biotherapeutics has launched with $103 million in committed financing to develop genetic medicines targeting serious kidney diseases, beginning with autosomal dominant polycystic kidney disease. The financing includes a $93 million Series A led by RA Capital Management with participation from Deep Track Capital, Biogen New Ventures, UPMC Enterprises, Pivotal bioVenture Partners, the National Kidney Foundation Innovation Fund and a family office connected to an individual living with ADPKD. 4BIO Capital and GV, which co-led Estuary's $10 million seed financing, also participated.